What Does IO Biotech Do?

Total employees92
HeadquartersCopenhagen N
Founded2015

IO Biotech is a clinical-stage biopharmaceutical company pioneering the discovery and development of novel, immune-modulating T-win® technology-based cancer therapies. The company is focused on activating the patient's own immune system to recognize and eradicate cancer cells. IO Biotech's lead candidates, IO102 and IO103, are designed to target immunosuppressive mechanisms mediated by IDO and PD-L1, respectively, and are being evaluated in clinical trials for various cancer indications, including in combination with anti-PD-1 checkpoint inhibitors.

Where Is IO Biotech's Headquarters?

HQ Function

Serves as the central hub for IO Biotech's research and development, clinical operations, corporate strategy, and administrative functions, guiding the company's global efforts in immuno-oncology.

Notable Features:

Located within the Copenhagen Bio Science Park (COBIS), a leading life science cluster, offering access to advanced research infrastructure, collaborative networks, and a dynamic innovation ecosystem.

Work Culture:

A dynamic, science-focused, and collaborative work culture prevails, with employees dedicated to advancing innovative cancer therapies. Emphasis is placed on teamwork, scientific rigor, and a patient-first mindset.

HQ Significance:

The Copenhagen headquarters is strategically important, leveraging Denmark's strong biotech sector and facilitating R&D, clinical development, and partnerships within Europe and globally.

Values Reflected in HQ: The headquarters embodies IO Biotech's core values of innovation, scientific excellence, collaboration, and a relentless commitment to developing transformative treatments for cancer patients.

Location:

IO Biotech maintains a focused global presence, primarily centered around its research and development operations in Denmark and its clinical and business operations in the United States. The company supports global clinical trials across multiple countries in North America and Europe, collaborating with leading research institutions and contract research organizations (CROs) worldwide to advance its pipeline of novel immuno-oncology therapies.

Street Address:

Ole Maaløes Vej 3

City:

Copenhagen N

State/Province:

Capital Region of Denmark

Country:

Denmark

Where Else Does IO Biotech Operate Around the World?

New York, NY, USA

Address: 55 Broad Street, Suite 220, New York, NY 10004

To establish a strong operational footprint in the United States, facilitating clinical development, regulatory interactions, access to capital markets, and strategic collaborations essential for IO Biotech's growth and the advancement of its therapies.

Buying Intent Signals for IO Biotech

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading IO Biotech? Meet the Executive Team

As of April 2025, IO Biotech' leadership includes:

Mai-Britt Zocca, PhD - President & CEO, Founder
Qasim Ahmad, MD - Chief Medical Officer
Keith L. Ungar - President, U.S. Operations, General Counsel & Corporate Secretary
Eva Steiness, MD, DMSc - Chief Operating Officer
Amy Sullivan - Chief Financial Officer
Muhammad Al-Hajj, PhD - Chief Scientific Officer

Who's Investing in IO Biotech?

IO Biotech has been backed by several prominent investors over the years, including:

Novo Holdings
Lundbeckfonden BioCapital (formerly Lundbeckfonden Emerge)
Sunstone Life Science Ventures
Kurma Partners
Vaekstfonden (The Danish Growth Fund)
Samsara BioCapital
Various public institutional investors (post-IPO)

What Leadership Changes Has IO Biotech Seen Recently?

Hire2
Exits1

Over the past 12 months (May 2023 - May 2024), IO Biotech has made significant leadership appointments, including a new Chief Medical Officer in May 2023 and a new Chief Scientific Officer in September 2023. These changes underscore the company's commitment to advancing its clinical programs. The transition in the Chief Scientific Officer role also occurred during this period.

Departures

Mac M. MacDonald, PhD, Mac M. MacDonald, PhD, departed from his role as Chief Scientific Officer.

New Appointments:

Qasim Ahmad, MD, Qasim Ahmad, MD, was appointed as the new Chief Medical Officer.
Muhammad Al-Hajj, PhD, Muhammad Al-Hajj, PhD, was appointed as the new Chief Scientific Officer.

What Technology (Tech Stack) Is Used byIO Biotech?

Discover the tools IO Biotech uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

IO Biotech Email Formats and Examples

IO Biotech commonly uses the [first].[last]@iobiotech.com email format for its employees. While other formats might exist in smaller numbers, this is the most prevalent pattern observed.

[first].[last]@iobiotech.com

Format

mai-britt.zocca@iobiotech.com

Example

75%

Success rate

What's the Latest News About IO Biotech?

GlobeNewswireMay 8, 2024

IO Biotech Announces First Quarter 2024 Financial Results and Provides Corporate Update

IO Biotech reported its Q1 2024 financial results, highlighting progress in its clinical trials, including the pivotal Phase 3 trial for IO102-IO103 in combination with pembrolizumab for metastatic melanoma, and outlined key upcoming milestones....more

GlobeNewswireApril 2, 2024

IO Biotech Presents New Preclinical Data on Novel Approaches to Enhance Anti-Tumor Immunity at the AACR Annual Meeting 2024

IO Biotech presented promising new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2024, showcasing innovative strategies to boost the immune system's ability to fight tumors, further supporting its T-win technology platform....more

GlobeNewswireFebruary 28, 2024

IO Biotech Announces Full Year 2023 Financial Results and Provides Corporate Update

IO Biotech reported its full-year 2023 financial results and provided a comprehensive update on its corporate strategy, clinical trial advancements for its lead candidates IO102-IO103, and anticipated developments for 2024....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including IO Biotech, are just a search away.